McCarthy Sean A.'s Form 4 filing
CytomX Therapeutics, Inc. (CTMX) · filed Jul 21, 2022
- Accession no.
- 0001567619-22-014299
- Filed
- Jul 21, 2022
- Trade date
- Jul 19-20, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $21.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McCarthy Sean A.CIK 0001654058 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 19, 2022 | Common Stock | AGrant or awardAcquired | +40,000 | $0.00 | $0 | 305,853 | Direct | |
| Jul 20, 2022 | Common Stock | SSaleDisposed | −14,911 | $1.42 | −$21,173.62 | 290,942 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.